GlassScriptPhysician profile
Victor Doan
NPI 1366733693
$3,007.72
in general payments reported to CMS, 2019-2025
21 companies · $147 in 2025
The $147 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $60.66 · 2021: $410 · 2022: $955 · 2023: $660 · 2024: $775 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,060.10 | 2020-2025 | |
| Ucb, INC. | $609.96 | 2021-2025 | Briviact, Rystiggo |
| Argenx US, INC. | $299.32 | 2022-2025 | Vyvgart Hytrulo |
| Eisai INC. | $158.07 | 2020-2024 | |
| Csl Behring | $130.87 | 2021-2022 | |
| Silk Road Medical, INC. | $107.15 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Novartis Pharmaceuticals Corporation | $104.60 | 2024 | |
| Lundbeck LLC | $103.93 | 2022 | |
| Lilly USA, LLC | $84.07 | 2024 | Kisunla, Reyvow, Emgality |
| Amgen INC. | $69.90 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $49.67 | 2021 | |
| Upsher-Smith Laboratories LLC | $41.65 | 2021-2022 | |
| Horizon Therapeutics Plc | $26.26 | 2022 | |
| Biogen, INC. | $23.59 | 2022 | |
| Allergan, INC. | $22.77 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $20.76 | 2021 | |
| Neurelis, INC. | $20.68 | 2022 | |
| Supernus Pharmaceuticals, INC. | $20.15 | 2021 | |
| Alexion Pharmaceuticals, INC. | $20.10 | 2022 | |
| Nevro Corp. | $19.91 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.